



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: J. Timothy GREENAMYRE, et al
Serial No.: 09/148,973 Group No.: 1627
Filed: September 4, 1998 Examiner.: Maurice Garcia Baker
For: METHODS OF ADMINISTERING AN AMPA RECEPTOR ANTAGONIST
TO TREAT DYSKINESIAS ASSOCIATED WITH DOPAMINE AGONIST
THERAPY

Attorney Docket No.: U 946765-7

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION UNDER 37 CFR 1.132

I, Frank S. Menniti, PhD, hereby declare:

1. My technical background and experience are as described in my curriculum vitae which is annexed hereto as Exhibit 1. I submit this declaration in connection with the prosecution of the above US patent application ("the application"). I am a co-inventor of the subject matter described and claimed in the application and am fully familiar with its contents.
2. The application describes and claims a method of treating dyskinesia associated with dopamine agonist therapy in a mammal which comprises administering to the mammal an amount of an AMPA receptor antagonist that is effective in treating such dyskinesia. A person of ordinary skill in the art at the time of filing the application, September 4, 1998, would have been a neurologist or a person with a degree in neurology. Such person of ordinary skill in the art would have been familiar with the references cited below, which are also listed in Exhibit 2, annexed hereto.

3. As of the application filing date, it was known that the use of therapies that directly stimulate dopamine receptors such as the chronic administration of dopamine agonist therapy in the treatment of Parkinson's disease, could provoke motor abnormalities, including choreatic dyskinesias and dystonias (see the application at page 1, lines 18-25). I understand that an issue has arisen in the prosecution of the application as to whether the disclosure in Arnold et al US Patent 5,670,516 ("Arnold et al") would have provided one of skill in the art with a reasonable expectation of success in the treatment of such dopamine agonist-induced dyskinesias by the administration of an AMPA receptor antagonist. To address this issue, it is first necessary to determine what one of skill in the art would have understood from the Arnold et al disclosure.

4. Arnold et al teach that blocking AMPA receptors is an effective way to treat certain neurological disorders, including but not limited to drug-induced Parkinson's Disease and tardive dyskinesia (Arnold et al at column 1, line 55 to column 2, line 9). Arnold et al do not, however, disclose that the blocking of AMPA receptors would be an effective way to treat all neurological disorders, regardless of etiology, and they specifically do not disclose that the blocking of AMPA receptors would be an effective way to treat a dyskinesia associated with dopamine agonist therapy. The question then is whether the teaching in Arnold et al that one can treat certain neurological disorders, such as tardive dyskinesia, by blocking AMPA receptors would provide one of skill in the art with an expectation that one can treat dopamine agonist-induced dyskinesias in the same way. In answering this question, it is important to understand that when neurological disorders, such as tardive dyskinesia,

are classified by their etiology, the fact that different disorders fall within the same classification (e.g., "dyskinesia") does not mean that they can be successfully treated with the same therapy, as next discussed.

5. Tardive dyskinesia (TD) is one in a broad category of movement disorders thought to involve pathology of the basal ganglia, which category also includes Parkinson's disease, drug-induced parkinsonism, the choreas, ballism, the athetoses, the dystonias including tardive (and other) dystonias, akathisia, Huntington's disease, and several degenerative and atrophic syndromes, (see US Patent 5,670,539 at column 5, line 61-column 6, line 7). As of the filing date of the application, it was poorly understood how basal ganglia control movements, and it was thought that the manifestation of abnormal movement disorders, such as TD, at a minimum involved several neurotransmitter systems, and that vulnerability to such disorders might be multifaceted (US Patent 5,670,539 at column 7, lines 3-7). Significantly one facet of this vulnerability was thought to involve an imbalance in serotonin-dopamine interactions in the brain (US Patent 5,670,539 at column 8, line 60-column 9, line 5).

6. In view of the diverse and multifaceted nature of the movement disorders and the apparent involvement of a number of different neurotransmitter systems, including neurotransmitter system(s) involving dopamine, one of skill in the art could not have predicted that a dyskinesia associated with a dopamine **agonist** therapy could be effectively treated in the same manner as a dyskinesia associated with a dopamine **antagonistic** therapy. In particular, one of skill in the art could not have known what

effects administering an AMPA receptor antagonist could have on the serotonin-dopamine interactions in patients treated with L-dopa and whether such effects would, for example, offset or exacerbate the effects caused by the dopamine agonist therapy.

7. Indeed, data in the literature at the time of our application and Arnold et al indicated that an AMPA receptor antagonist would potentiate dopamine agonist-induced dyskinesias. Specifically, Klogether et al (Klockgether et al., 1991) and Loschmann et al (Loschmann et al., 1991) demonstrated that an AMPA receptor antagonist potentiates the effects of a dopamine agonist in animal models of bradykinesia, one of the neurological symptoms of Parkinson's disease. This data suggests that AMPA receptor antagonists and dopamine agonists act synergistically in producing behavioral responses. We found, instead, that in the case of dopamine agonist-induced dyskinesias, AMPA receptor antagonists oppose the effect of dopamine agonists. Thus, our claim that an AMPA antagonist inhibits dopamine agonist-induced dyskinesias was unanticipated and contraindicated at the time of publication of Arnold et al.

8. I understand that an issue has also arisen as to whether the disclosure in Papa and Chase, Annals of Neurology, 39(5), pp. 574-578 (referred to by the Examiner as Stella et al) would have provided one of skill in the art with a reasonable expectation of success in the use of AMPA receptors to treat dopamine agonist-induced dyskinesias since these authors teach that an NMDA receptor antagonist can reduce L-DOPA-induced dyskinesias and since AMPA and NMDA receptors are subtypes of the same

receptor. However, while it is true that AMPA and NMDA receptors are both ionotropic glutamate receptors, it is well known that these two receptors have clearly distinct physiologies (Seuberg, 1993; Dingledine et al., 1999). Consistent with this fact are the numerous reports in the literature that AMPA and NMDA receptor antagonists have very different physiological effects (Browne and McCulloch, 1994; Durmuller et al., 1994; Sheardown et al., 1993; Papa et al., 1993). Thus, the observation by Papa and Chase that an NMDA receptor antagonist reduced dopamine agonist-induced dyskinesias would not have led to the deduction of the utility of an AMPA receptor antagonist to treat dopamine agonist-induced dyskinesias. AMPA and NMDA receptors serve distinct physiological functions and antagonists for the two receptor classes have distinct physiological effects. In fact, in light of the papers by Klockgether et al and Loschmann et al, the use of an AMPA receptor antagonist to treat dopamine agonist-induced dyskinesias was contraindicated prior to the application.

9. In view of the above, it is my belief that there is no disclosure in the prior art, including the Arnold et al patent and the Papa and Chase article, from which one of skill in the art could have expected that blocking AMPA receptors would be an effective way to treat a dyskinesia associated with dopamine agonist therapy.

10. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false

statements and the like so made are punishable by fine or imprisonment, or both,
under Section 1001 of Title 18 of the United States Code and that such willful false
statements may jeopardize the validity or the application of any patent issued thereon.

Date: 2-6-2004



Frank S. Menniti, PhD

EXHIBIT 1

CURRICULUM VITAE

Name: Frank S. Menniti, Ph.D.

Date & Place of Birth: May 10, 1956; Sewickley, PA

Citizenship: United States

Current Home Address: 10 Reynolds Hill Road
Mystic, Connecticut 06355
Telephone: (860)572-1343

Current Work Address: Pfizer Global Research and Development
Eastern Point Road
Groton, Connecticut 06340
Telephone: (860)441-5939
mennitis@groton.pfizer.com

Education:

09/83 - 12/87 Ph.D., Pharmacology, University of North Carolina, Chapel Hill, North Carolina

09/78 - 09/81 M.S., Neuroendocrinology, Massachusetts Institute of Technology, Cambridge, Massachusetts

09/74 - 06/78 B.A., Psychology, Franklin and Marshall College, Lancaster, Pennsylvania

Brief Chronology of Research Experience:

04/92 - Date Principal Research Investigator, Pfizer Global Research and Development. Principal investigator in development of therapies for the treatment of neurodegenerative and psychiatric diseases.

01/88-04/92 Senior Staff Fellow, National Institute of Environmental Health Sciences. Principal investigator in studies of receptor regulation and signal transduction through the inositol phosphate/intracellular calcium signaling cascade.

04/82 - 01/88 Research Biochemist, Wellcome Research Laboratories and graduate student, University of North Carolina. Principal investigator in studies of catecholamine biosynthesis and the role of ascorbic acid in bovine adrenomedullary chromaffin cells.

09/81 - 04/82 Research Assistant II, Harvard Medical School. Conducted biochemical and behavioral studies on peptide hormonal regulation of maternal behavior in the rat.

09/78 - 09/81 Graduate student, Massachusetts Institute of Technology. Principal investigator in biochemical and behavioral studies into the interaction of steroid hormones and neurotransmitters in the rat central nervous system.

09/77 - 06/78 Undergraduate student, Franklin and Marshall College. Independent study into the role of olfaction and spatial cues in maze performance and into the psychopharmacology of exploratory behavior in rodents.

06/77 - 08/77 Participant in the National Science Foundation Undergraduate Research Program, Brown University. Participated in studies of observing responses and eye movement during choice behavior in the stump-tail macaque.

Awards and Honors:

06/78 Phi Beta Kappa
10/77 Psi Chi, Psychology Honor Society

Affiliations:

Sigma Xi, Scientific Research Society
Society for Neuroscience

PUBLICATIONS

Menniti, F. S.: Sex steroid/mesolimbic dopamine interaction: Behavioral and biochemical evidence. *Masters Thesis*: Massachusetts Institute of Technology, 1980.

Menniti, F. S., and Baum, M. J.: Differential effects of estrogen and androgens on locomotor activity induced in castrated male rats by amphetamine, a novel environment, or apomorphine. *Brain Res.* **216**:89-107, 1981.

Menniti, F. S., Erskine, M. S., and Baum, M. J.: Persistence of dihydrotestosterone inhibition of lordosis in estrogen-primed rats fed a tryptophan-deficient diet. *Brain Res. Bull.* **7**:1-4, 1981.

Menniti, F. S., Erskine, M. S., Tobet, S. A., and Baum, M. J.: Dihydrotestosterone-induced inhibition of lordosis in estrogen-primed ovariectomized rats following 6-hydroxydopamine or electrolytic septal lesions. *Pharmacol. Biochem. Behav.* **16**:211-216, 1982.

Rubin, B., Menniti, F. S., and Bridges, R. S.: Intracerebroventricular administration of oxytocin and maternal behavior in rats after prolonged and acute steroid pretreatment. *Hormones and Behav.* **17**:45-53, 1983.

Menniti, F. S., Knoth, J., and Dilberto, E. J., Jr.: Role of ascorbic acid in dopamine β -hydroxylation: The endogenous cofactor and putative electron donor for cofactor regeneration. *J. Biol. Chem.* **261**:16901-16908, 1986.

Menniti, F. S., Knoth, J., Peterson, D. S., and Dilberto, E. J., Jr.: The *in situ* kinetics of dopamine β -hydroxylase in bovine adrenomedullary chromaffin cells: Intravesicular compartmentation reduces apparent affinity for the cofactor ascorbate. *J. Biol. Chem.* **262**:7651-7657, 1987.

Dilberto, E. J., Jr., Menniti, F. S., Knoth, J., Daniels, A. J., Kizer, S. J., and Viveros, O. H.: Adrenomedullary chromaffin cells as a model to study the neurobiology of ascorbic acid: From monooxygenation to neuromodulation. *Annals N.Y. Acad. Sci.* **498**:28-53, 1987.

Menniti, F. S.: The roles of ascorbic acid in dopamine β -hydroxylation. *Doctoral Thesis*, University of North Carolina, Chapel Hill, North Carolina, 1987.

Dilberto, E. J., Jr., Menniti, F. S., and Knoth, J.: Co-transmitter biosynthesis in the adrenal medulla chromaffin cell: Ascorbic acid availability. In: *Progress in Catecholamine Research, Part A: Basic Aspects and Peripheral Mechanisms*. Alan R. Liss, Inc., pp. 279-285, 1988.

Menniti, F. S., and Dilberto, E. J., Jr.: Newly-synthesized dopamine as precursor for norepinephrine biosynthesis in bovine adrenomedullary chromaffin cells. *J. Neurochem.* **53**:890-897, 1989.

Menniti, F. S., Takemura, H., Sugiya, H., and Putney, J. W., Jr.: Mechanisms of receptor regulation for the phosphoinositide signalling systems. In: Vanderhoek, J. Y., ed., *Biology of Cellular Transducing Signals*. New York, Plenum Publishing Corp., 61-72, 1990.

Menniti, F. S., Oliver, K. G., Nogimori, K., Obie, J., Shears, S. B., and Putney, J. W., Jr.: Origins of inositol tetrakisphosphates in agonist-stimulated rat pancreatoma cells: Stimulation

by bombesin or inositol (1,3,4,5,6) pentakisphosphate breakdown to inositol (3,4,5,6,7)tetraakisphosphate. *J. Biol. Chem.*, **265**:11167-11176, 1990.

Nogimori, K., Menniti, F. S., and Putney, J. W., Jr.: Identification in extracts from AR4-2J cells of inositol (1,4,5)trisphosphate by its susceptibility to inositol (1,4,5)trisphosphate 3-kinase and 5-phosphatase. *Biochem. J.*, **269**:195-200, 1990.

Menniti, F. S. and Putney, J. W., Jr.: Inositol 1,4,5-trisphosphate 3-kinase activity in high-speed supernatants from rat pancreatic cells, AR4-2J. *Biochem. J.*, **274**:621-622, 1991.

Menniti, F. S., Bird, G. St. J., Takemura, H., Thastrup, O., Potter, B.V., and Putney, J. W., Jr.: Mobilization of calcium from permeabilized rat parotid acinar cells: Evidence for translocation of calcium from uptake to release sites within the inositol (1,4,5)trisphosphate- and thapsigargin-sensitive calcium pool. *J. Biol. Chem.*, **266**:13646-13653, 1991.

Putney, J. W., Jr., Bird, G. St. J., Horstman, D. A., Hughes, A. R., Menniti, F. S., Nogimori, K., Obie, J., Oliver, K. G., Sugiya, H., and Takemura, H.: Role of inositol phosphates in the actions of substance P on NK₁ receptors in exocrine gland cells. *Annals N.Y. Acad. Sci.*, **632**:94-102, 1991.

Menniti, F. S., Takemura, H., and Putney, J. W., Jr.: Different modes of regulation for phospholipase C-linked receptors in the rat pancreatic cell line, AR4-2J. *Mol. Pharmacol.*, **40**:727-733, 1991.

Bird, G. St. J., Takemura, H., Thastrup, O., Putney, J. W., Jr., and Menniti, F. S.: Mechanism of agonist-induced Ca^{2+} mobilization in the rat pancreatic cell line, AR4-2J. *Cell Calcium*, **13**:49-59, 1992.

Menniti, F. S., Bird, G. St. J., Glennon, M. C., Obie, J. F., Rossier, M. F., and Putney, J. W., Jr.: Inositol Polyphosphates and Calcium Signalling. *Molecular and Cellular Neurosciences*, **3**:1-10, 1992.

Menniti, F. S., Bird, G. St. J., Glennon, M. C., Nogimori, K., Obie, J. F., Oliver, K. G., Rossier, M. F., and Putney, J. W., Jr.: Phosphoinositides and Intracellular Calcium. In: Brody, J. S., Tkachuk, V., and Center, D., eds. *Signal Transduction in Lung Cells*. New York, Marcel Dekker, Inc., pp 111-145, 1993.

Menniti, F. S., Oliver, K. G., Putney, J. W., Jr., and Shears, S. B.: Inositol phosphates and cell signalling: New views of InsP₅ and InsP₆. *Trends in Biochemical Sciences*, **18**:53-56, 1993.

Menniti, F. S., Miller, R.M., Putney, J. W., Jr., and Shears, S. B.: Rapid turnover of inositol polyphosphate pyrophosphates in pancreatic cells. *J. Biol. Chem.*, **268**:3850-3856, 1993.

Chenard, B. L., Butler, T. W., Menniti, F. S., Prochniak, M. A., and Richter, K. E. G.: A short synthesis of GYKI 52466. *Bioorg. Med. Chem. Lett.*, **3**:1991-1992, 1993.

Chenard, B. L., Bordner, J., Butler, T. W., Chambers, L. K., De Costa, D. L., Ducat, M. F., Dumont, C. B., Mena, E. E., Menniti, F. S., Neilsen, J., Pagnozzi, M.J., Richter, K. E. G., Ronau, R. T., Shalaby, I. A., Stemple, J. Z. and White, W. F.: CP-101,606: A potent new neuroprotectant which blocks N-methyl-D-aspartate responses. *J. Med. Chem.*, **38**:3138-3145 1995.

Menniti, F.S., Chenard, B.L., Collins, M.A., Ducat, M.F., Shalaby, I.A., and White, W.F.: CP-101,606, a Potent Neuroprotectant Selective for Forebrain Neurons. *Eur. J. Pharmacol.*, **331**:117-126, 1997.

Taniguchi, K., Shinjo, K., Mizutani, M., Shimada, K., Ishikawa, T., Menniti, F.S. and Nagahisa, A.: Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. *Br. J. Pharmacol.*, **122**, 809-812, 1997.

Butler, T.W., Blake, J.F., Bordner, J., Butler, P., Chenard, B.L., Collins, M.A., DeCosta, D., Ducat, M.J., Eisenhard, M.E., Menniti, F.S., Pagnozzi, M.J., Sands, S.B., Segelstein, B.E., Volberg, W., White, W.F., and Zhao, D.: 3R, 4S, 3-[4-(4-Fluorophenyl)-4-hydroxy-piperidin-1-yl]-chroman-4,7-diol: A Conformationally Restricted Analog of the NR2B Subtype Selective NMDA Antagonist (1S, 2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol. *J. Med. Chem.*, **41**:1172-1184, 1998.

Menniti, F.S., Shah, A.H., Williams, S.A., Wilner, K.D., White, W.F., and Chenard, B.L. CP-101,606: An NR2B Selective NMDA Receptor Antagonist. *CNS Drug Reviews*, **4**:307-322, 1998.

Chenard, B.L. and Menniti F.S. Antagonists Selective for NMDA Receptors Containing the NR2B Subunit. *Current Pharmaceutical Design*, **5**:381-404, 1999.

Menniti, F.S., Pagnozzi, M.J., Butler, P., Chenard, B.L., Jaw-Tsai, S.S., and White, W.F. CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced fos expression and cortical spreading depression in rodents. *Neuropharmacol.*, **39**:1147-1155, 2000

Steece-Collier, K., Chambers, L. K., Menniti, F. S., Jaw-Tsai, S. S. and Greenamyre, J. T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit containing N-methyl-D-aspartate receptors. *Exp. Neurol.*, **163**:239-243, 2000

Chenard, B.L., Menniti, F.S., Pagnozzi, M.J., Shenk, K.D., Ewing, F.E., and Welch W.M. Methaqualone derivatives are potent non-competitive AMPA receptor antagonists. *Bioorg. Med. Chem. Lett.*, **10**:1203-1205, 2000.

Menniti, F.S., Chenard, B. L., Collins, M. B., Ducat, M. F., Ewing, F.E., Huang, J.I., Kelly, K.A., Lazzaro, J.T., Pagnozzi, M.J., Weeks, J.A., Welch, W.A., and White, W.F. Characterization of the binding site for a novel class of noncompetitive AMPA receptor antagonists. *Mol. Pharm.*, **58**:1310-1317, 2000.

Welch, W.M. , Ewing, F.E., Huang, J., Menniti, F.S., Pagnozzi, M.J., Kelly, K.A., Seymour, P.A., Guanowski, V., DeVries, K., Sakhar, V., Guhan, S., Guinn, M.R., Critchett, D., Lazzaro, J., Ganong, A.H., and Chenard B.L. Atropisomeric quinazolin-4-one derivatives are potent non-competitive α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists. *Bioorg. Med. Chem. Lett.* **11**:177-181, 2001.

Chenard, B.L., Welch W.M., Blake, J.F., Butler, T.A., Reinhold, A., Ewing, F.E., Menniti, F.S., and Pagnozzi, M.J. Quinazolin-4-one α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

(AMPA) receptor antagonists: Structure-activity relationship of the C-2 side chain tether. *J. Med. Chem.*, **44**:1710-1717, 2001.

Laziaro, J.T., Paternain, A.V., Lerma, J., Chenard, B.L., Ewing, F.E., Huang, J., Welch, W.M. and Menniti, F.S. Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. *Neuropharmacol.*, **42**:143-153, 2002.

Menniti, F.S., Buchan, A., Chenard, B.L., Critchett, D.J., Guanowsky, V., Seymour, P.A., and Welch, W.M. CP-465,022, a selective noncompetitive AMPA receptor antagonist, is antiseizurogenic but not neuroprotective *in vivo*. *Stroke*, **34**:171-176, 2003.

Grasso, S., Micale, N., Zappalà, M., Galli, A., Costagli, C., Menniti, F.S., and De Micheli, C. Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. *Bioorg. Med. Chem. Lett.*, **13**:443-446, 2003.

Ramirez, A.D., Liu, X., and Menniti, F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. *Neuroendocrinol.*, **77**:223-231, 2003.

Ramirez, A.D., Wong, S. K.-F., and Menniti, F.S. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. *Eur. J. Pharmacol.*, **475**:29-35, 2003.

Seeger, T.F., Bartlett, B., Coskran, T.M., Culp, J.M., James, L.C., Krull, D.L., Lanfear, J., Ryan, A.M., Schmidt, C.J., Strick, C.A., Varghese, A.H., Williams, R.D., Wylie, P.G., and Menniti, F.S. Immunohistochemical localization of PDE10A in the rat brain. *Brain Res.*, **985**:113-126, 2003.

Zappalà, M., Grasso, S., Micale, N., Zuccalà, G., Menniti, F.S., De Sarro, G., and De Micheli, C. 1-Aryl-6,7-methylenedioxy-3H-quinazolin-4-ones as Anticonvulsant Agents. *Bioorg. Med. Chem. Lett.*, **13**:44273-4430, 2003.

Nash, J.E., Ravenscroft, P., McGuire, S., Crossman, A.R., Menniti, F.S., and Brotchie, J.M. The effects of systemic administration of the NR2B-selective NMDA receptor antagonist CP-101,606 in the MPTP-lesioned marmoset model of Parkinson's disease. *Exp. Neurol.* Submitted

Wessell, R.H., Ahmed, S.M., Menniti, F.S., Dunbar, G.L., Chase, T.N., and Oh, J.D. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. *Neuropharmacol.* Submitted

Richter, K.E.G., Pagnozzi, M.J., Lazzaro, J.T., Ganong, A.H., White, W.F. and Menniti, F.S., Different modes of calcium signaling through the NMDA Receptor: Dependence on the level of receptor activation. *Neuroscience*, in preparation.

PATENTS

Issued

Chenard, B. L., Welch, W.M., and Menniti, F. S. Methods of administering an AMPA receptor antagonist to treat dyskinésias associated with dopamine agonist therapy. US 6,136,812, Oct 24, 2000.

Chenard, B. L. and Menniti, F. S. Combinations for the treatment of parkinsonism containing selective NMDA antagonists. US 6,258,827, Jul 10, 2001.

Published applications

Ahlijanian, M.K., Cooper, C.B., Seymour, P.A., and Villalobos, A. Imidazole derivatives. Pfizer Products Inc. WO0210141. Published 2-7-2002. Filed 7-25-2001.

Chenard, B.L., Menniti, F.S., and Saltarelli, M.D. Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists. Pfizer Products Inc. EP1199067. Published 4-24-2002. Filed 9-28-2001.

Chenard, B.L., Menniti, F.S., and Saltarelli, M.D. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist. Pfizer Products Inc. EP1186303. Published 3-13-2002. Filed 8-24-2001.

Chenard, B.L., Greenamyre, J.T., Menniti, F.S., and Welch, W.M., Jr. Quinazoline-4-one AMPA antagonists for the treatment of dyskinésias associated with dopamine agonist therapy. Pfizer Products Inc. EP0900567. Published 3-10-1999. Filed 8-20-1998.

Chenard, B.L., Menniti, F.S., and Saltarelli, M.D. NMDA NR2B antagonists for treating depression and neurodegenerative disorders. Pfizer Products Inc. EP1199068. Published 4-24-2002. Filed 9-28-2001.

Chenard, B.L., Menniti, F.S., and Welch, W.M., Jr. AMPA antagonists for the treatment of dyskinésias associated with dopamine agonist therapy. Pfizer Products Inc. EP0900568. Published 3-10-1999. Filed 9-4-1998.

Chenard, B.L., Menniti, F.S., and Saltarelli, M.D. Pharmaceutical combinations for the treatment of stroke and traumatic brain injury. Pfizer Products Inc. EP1186304. Published 3-13-2002. Filed 9-4-2001.

Lebel, L.A., Menniti, F.S., and Schmidt, C.J. Use of selective PDE10 inhibitors for the treatment of neurological and psychiatric disorders. Pfizer Products Inc. PC10885. Filed 4-20-2001.

Filed applications

James, L.C., Lebel, L.A., Menniti, F.S., and Strick, C.A. PDE10 cell-based assay and sequences. Pfizer Products Inc. PC23111. Filed 7-31-01.

McNeish, J.D., Menniti, F.S., Schmidt, C.J., and Stock, J.L. PDE10 knock-out mice. Pfizer
Products Inc. PC23257. Filed 12-20-01.

ABSTRACTS AND PRESENTATIONS

Menniti, F. S., Rudorfer, B., and Baum, M. J.: Differential effects of 17 β -estradiol, 5a-dihydrotestosterone, and testosterone on drug-induced locomotion in castrated rats. *Society for Neuroscience, 10th Annual Meeting, Abstract 128.14*, 1980.

Menniti, F. S., and Diliberto, E. J., Jr.: Evidence for recycling of ascorbic acid during dopamine β -hydroxylation in chromaffin cells. *Society for Neuroscience, 13th Annual Meeting, Abstract 290.4*, 1983.

Menniti, F. S., and Diliberto, E. J., Jr.: Multiple pools of tyrosine and dopamine in adrenal chromaffin cells: Evidence for preferential utilization of newly taken-up tyrosine and newly synthesized dopamine in norepinephrine biosynthesis. *Society for Neuroscience, 14th Annual Meeting, Abstract 258.9*, 1984.

Diliberto, E. J., Jr., Daniels, A. J., and Menniti, F. S.: Studies on ascorbic acid in adrenomedullary chromaffin cells: Catecholamine synthesis and cholinergic receptor-dependent and -independent release. *International Symposium of the Molecular Biology of Peripheral Catecholamine Storing Tissues, Abstracts p 113*, Colmar, France, 1984.

Diliberto, E. J., Jr., Menniti, F. S., and Knoth, J.: Adrenomedullary chromaffin vesicle dynamics: Availability of ascorbic acid for dopamine- β -hydroxylation. *10th International Society for Neurochemistry, Riva del Garda, Italy, 1985*.

Menniti, F. S., and Diliberto, E. J., Jr.: Ascorbic acid in bovine chromaffin cells: Further evidence for recycling of cofactor during dopamine β -hydroxylation. *FASEB Summer Research Conference on Neurotransmitters, Saxton River, Vermont, USA, 1985*.

Diliberto, E. J., Jr., Menniti, F. S., Knoth, J., Daniels, A. J., Kizer, S. J., and Viveros, O. H.: Adrenomedullary chromaffin cells as a model to study the neurobiology of ascorbic acid: From monooxygenation to neuromodulation. *New York Academy of Sciences Conference on Vitamin C, Abstract 3, New York, New York, USA, 1986*.

Diliberto, E. J., Jr., Menniti, F. S., Knoth, J., Kizer, S. J., and Viveros, O. H.: Regeneration of ascorbic acid for dopamine β -hydroxylation and peptidyl-glycine α -amidation. *3rd International Symposium on Chromaffin Cell Biology, Coolfont, Berkeley Springs, West Virginia, USA, 1986*.

Menniti, F. S., and Diliberto, E. J., Jr.: *In situ* kinetics of dopamine- β -hydroxylase in bovine chromaffin cells. *FASEB Summer Research Conference on Neurotransmitters, Keystone, Colorado, USA, 1987*.

Diliberto, E. J., Jr., Menniti, F. S., and Knoth, J.: Co-hormone biosynthesis in the adrenal medulla chromaffin cell: Cofactor availability. *6th International Catechol-amine Symposium, Jerusalem, Israel, 1987*.

Menniti, F. S., Takemura, H., and Putney, J. W., Jr.: Three modes of regulation for peptide hormone receptors activating phospholipase C in AR4-2J cells. *Biology of Cellular Transducing Signals '89, IXth International Washington Spring Symposium, Washington, D.C., USA, 1989*.

Takemura, H., Menniti, F. S., and Putney, J. W., Jr.: Regulation of peptide hormone receptors linked to Ca^{2+} mobilization in AR4-2J cells. *Biology of Cellular Transducing Signals '89, IXth International Washington Spring Symposium*. Washington, D.C., USA, 1989.

Takemura, H., Menniti, F. S., and Putney, J. W., Jr.: Four modes of regulation for peptide hormone receptors linked to inositol phosphate formation and Ca^{2+} mobilization in AR4-2J cells. *7th International Conference on Cyclic Nucleotides, Calcium, and Protein Phosphorylation*. Kobe, Japan, 1989.

Kwan, C.-Y., Takemura, H., Menniti, F. S., Thastrup, O., and Putney, J. W., Jr.: Agonist-sensitive intracellular Ca^{2+} pool can be refilled via Ca^{2+} influx or re-cycling of intracellular Ca^{2+} in rat lacrimal cells and AR4-2J cells. *7th International Conference on Cyclic Nucleotides, Calcium, and Protein Phosphorylation*. Kobe, Japan, 1989.

Putney, J. W., Jr., Menniti, F. S., Bird, G. S., Oliver, K. G., and Shears, S. B.: Inositol phosphate metabolism and calcium signalling in non-excitable cells. *72nd Annual Meeting of the Endocrine Society*. Atlanta, Georgia, USA, 1990.

Menniti, F. S., Oliver, K. G., Nogimori, K., Obie, J., Shears, S. B., and Putney, J. W., Jr.: Stimulation by bombesin of inositol (1,3,4,5,6) pentakisphosphate breakdown to inositol (3,4,5,6)tetrakisphosphate in rat pancreatic cells. *XIth International Congress of Pharmacology*. Amsterdam, The Netherlands, 1990.

Shears, S., Abdulla, M., Hughes, P., Menniti, F., Marecek, J., and Prestwich, G.: Purification of (1,3,4)IP₃ 6-kinase and (3,4,5,6)IP₄ 1-kinase from rat liver homogenates using an IP₆-affinity resin. *FASEB Meeting*, Anaheim, California, USA, 1992.

Menniti, F. S., Richter, K. E. G., Ducat, M., Prochniak, M. A., and Pagnozzi, M.: Ca^{2+} influx through AMPA receptors in rat cerebellar granule cells. *Society for Neuroscience, 23rd Annual Meeting*, Abstract 196.14, 1993.

Menniti, F. S., Collins, M. A., Chenard, B. L., Shalaby, I. A., and White, W. F.: CP-101,606: A potent and selective antagonist of forebrain NMDA receptors: *In Vitro* neuroprotective activity. *Society for Neuroscience, 25th Annual Meeting*, 1995.

Ganong, A. H., Lazzaro, J. T., Richter, K. E. G., Tang, L.-H., Aizenman, E., Menniti, F. S., and White, W. F.: CP-101,606: A potent and selective antagonist of forebrain NMDA receptors: Effects on NMDA receptor-mediated ion flux. *Society for Neuroscience, 25th Annual Meeting*, 1995.

Pagnozzi, M. J., Chambers, L. K., Menniti, F. S., Chenard, B. L., and White, W. F.: CP-101,606: A potent and selective antagonist of forebrain NMDA receptors: *In vivo* activity. *Society for Neuroscience, 25th Annual Meeting*, 1995.

Richter, K. E. G., Pagnozzi, M. J., Lazzaro, J. T., Menniti, F. S.: Dissociation between NMDA receptor mediated intracellular calcium signalling and ion flux. *Society for Neuroscience, 26th Annual Meeting*, 1996.

Menniti, F.S., Butler, T.W., Chambers, L.K., Chenard, B.L., Collins, M.A., Ducat, M.F., Pagnozzi, M.J., Sands, S.B., Volberg, W., and White, W.F.: CP-283,097, a potent antagonist of forebrain NMDA receptors. *Society for Neuroscience, 27th Annual Meeting*, 1997.

Butler, T.W., Chenard, B.L., Collins, M.A., Ducat, M.F., Menniti, F.S., Pagnozzi, and White, W.F.: CP-283,097, a conformationally restricted analog of CP-101,606: Structure Activity Relations. *Society for Neuroscience, 27th Annual Meeting*, 1997.

Menniti, F.S., Collins, M., Ducat, M.F., Kelley, K.A., Pagnozzi, M.J., and Richter, K.E.G.: CP-465,022, A novel noncompetitive AMPA receptor antagonist: *in vitro* pharmacology. *Society for Neuroscience, 28th Annual Meeting*, 1998.

Welch, W.M., Huang, J.-H., Ewing, F.E., Menniti, F.S., Pagnozzi, M.J., Banker, M.J., Devries, K.M., and McCarthy, K.E. Discovery of a potent and selective series of noncompetitive quinoxalino[4,3-d]AMPA antagonists and the preparation of an AMPA site radioligand. *Society for Neuroscience, 28th Annual Meeting*, 1998.

Taniguchi, K., Shinjo, K., Mizutani, M., Shimada, K., Ishikawa, T., Menniti, F.S. and Nagahisa, A.: Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. *Society for Neuroscience, 28th Annual Meeting*, 1998.

Menniti, F.S., The evolving pharmacology of AMPA subtype glutamate receptors. *Symposium on New CNS Drugs*, Yale University School of Medicine, New Haven, CT. Oct 8-9, 1999

Menniti, F.S., CP-101,606: A probe for the therapeutic uses of NR2B subunit selective NMDA receptor antagonists. *ASPET/Fuller Symposium: The Neuropharmacology of Glutamate*, Baltimore, MD. Oct 14-15, 2000

Welch, W.M., Huang, J.-H., Ewing, F.E., Menniti, F.S., Pagnozzi, M.J., Banker, M.J., Atropisomerism Within Series of Non-competitive AMPA Antagonists, *PACIFICHEM 2000 International Chemical Congress of Pacific Basin Societies*, Honolulu, Hawaii, December 14-19, 2000

Ramirez, A.D., Menniti, F.S., Doran, S., and Lui, X. Chronic, but not acute, estradiol treatment prevents MPTP-induced dopamine depletion in mice. *Society for Neuroscience, 31st Annual Meeting*, 2001.

Richter, K.E.G., Cook, J.M., Pagnozzi, M.J., Lanyon, L.F., Dunaiskis, A.R., Sanner, M.A., Menniti, F.S., Schachter, J.B., and Lau, L.-F., Role of GSK3 β and CDK5 in basal tau phosphorylation at the AT8 epitope in cultured cortical neurons. *Society for Neuroscience, 31st Annual Meeting*, 2001.

Menniti, F.S., Strick, C.A., Seeger, T.F., and Ryan, A.M., Immunohistochemical localization of PDE10 in the rat brain. William Harvey Research Conference 'Phosphodiesterase in Health and Disease', Porto, Portugal, Dec 5-7, 2001.

Menniti, F.S., Brown, T.M., Collins, M.A., Fox, C.B., Kimmel, L.H., Kleiman, R.J., Schmidt, C.J., Shrikhande, A., Wong, S.K., PDE10 regulation of intracellular signaling in striatal medium spiny neurons in culture. Gordon Research Conference 'Cyclic Nucleotide Phosphodiesterases', Mt. Holyoke College, South Hadley, MA, Jun 23-28, 2002.

Kleiman, R.J., Brown, T.M., Collins, M.A., Fox, C.B., Kimmel, L.H., Menniti, F.S., Schmidt, C.J., Shrikhande, A., Wong, S.K., PDE10 regulation of intracellular signaling in striatal medium spiny neurons in culture. *Society for Neuroscience, 32nd Annual Meeting*, 2002.

Wylie, P.A., Strick, C.A., Seeger, T.F., and Ryan, A.M., Menniti, F.S., Immunohistochemical localization of PDE10 in the rat brain. *Society for Neuroscience, 32nd Annual Meeting*, 2002.

Ramirez, A.D., Menniti, F.S., Wong, S.K.F., Pramipexole inhibits MPTP toxicity in male mice: Reversal by the D3-selective antagonist Lu-201640. *Society for Neuroscience, 32nd Annual Meeting*, 2002.

Menniti, F.S., Brown, T.M., Collins, M.A., Fox, C.B., Kimmel, L.H., Kleiman, R.J., Lebel, L.A., Schmidt, C.J., Seeger, T.F., Shrikhande, A., Wong, S.K., and Wylie, P. Molecular mechanisms for the putative antipsychotic activity of PDE10A inhibitors. International Conference on Schizophrenia Research, Colorado Springs, CO, March 29-April 3rd, 2002

Siuciak, J.A., Chapin, D.S., Harms, J.F., Schmidt, C.J., Shrikhande, A., Wong, S.K.-F., Williams, R.D., Menniti, F.S., James, L.C., Strick, C.A., and McNeish, J.D., PDE10A Knockout mice: Behavioral characterization and effects of papaverine, a PDE10A inhibitor. International Conference on Schizophrenia Research, Colorado Springs, CO, March 29-April 3rd, 2002

EXHIBIT 2

References

1. Browne SE, McCulloch J (1994) AMPA Receptor Antagonists and Local Cerebral Glucose Utilization in the Rat. *Brain Res* 641: 10-20.
2. Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. [Review] [695 refs]. *Pharmacological Reviews* 51: 7-61.
3. Durmuller N, Criggs M, Meldrum BS (1994) The Effect of the Non-NMDA Receptor Antagonists, GYKI 52466 and NBQX and the Competitive NMDA Receptor Antagonist D- CPP on the Development of Amygdala Kindling and on Amygdala-Kindled Seizures. *Epilepsy Res* 17: 167-174.
4. Klockgether T, Turski L, Honoré T, Zhang Z, Gash DM, Kurlan R, Greenamyre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. *Ann Neurol* 30: 717-723.
5. Löschmann P-A, Lange KW, Kunow M, Rettig K-J, Jähnig P, Honoré T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. *J Neural Transm* 3: 203-213.
6. Papa SM, Engber TM, Boldry RC, Chase TN (1993) Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. *Eur J Pharmacol* 232: 247-253.
7. Seeburg PH (1993) The molecular biology of mammalian glutamate receptor channels. *Trends in Neurosci* 16: 359-365.
8. Sheardown MJ, Suzdak PD, Nordholm L (1993) AMPA, But Not NMDA, Receptor Antagonism Is Neuroprotective in Gerbil Global Ischaemia, Even When Delayed 24-h. *Eur J Pharmacol* 236: 347-353.
9. Richardson United States Patent No.: 5,670,539